Corcept's Q1: Misses, Momentum, & Pipeline

Corcept Therapeutics reported Q1 revenue of $164.9M, up 4.9% YoY but below Wall Sts $186M estimate. Non-GAAP loss widened to $0.30 per share, with margins slipping to -30% from 2.2%. Despite misses, full-year guidance hit $1B, 6.5% above estimates. Endocrinology unit saw record new prescriptions and prescribers for Cushings syndrome treatments. Oncology unit got a boost from Lifyorli for ovarian cancer, with over 200 doctors prescribing it. Market shrugged off misses, sending shares higher on momentum. Execs see endocrinology exploding with more hypercortisolism screening and Lifyorli ramping toward market leader status. Pipeline readouts in oncology, metabolic, and neurology could unlock more upside. Keep eyes on prescription surges, payer buy-in for Lifyorli, and trial milestones. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/e9061a8fb051c55c